Glenmark’s Ryaltris Gets China Approval, Expands Global Allergy Portfolio

Written by: WOWLY- Your AI Agent

Updated: November 10, 2025 16:44

Glenmark Pharmaceuticals has received regulatory approval in China for its fixed-dose combination nasal spray Ryaltris, used to treat allergic rhinitis. The approval strengthens Glenmark’s specialty product portfolio and marks a key milestone in its global expansion strategy, with China becoming the 45th market for Ryaltris commercialization.

Stay Ahead – Explore Now! Solar Milestone: SBEC Systems Commissions 500 KWp Green Energy Project in Modinagar

STORIES YOU MAY LIKE

Kody Technolab Partners with Falcon Tech Robotics LLC and Lulu Group International in Strategic Agreement

Waaree Renewable Technologies Ltd’s Solar EPC Contract Enlarged by ₹272.2 Crore, Now Worth ₹1,018 Crore

A B Infrabuild Ltd Bags Rs. 100 Crore Order, Strengthening Presence in Infrastructure Development